Home >  Registry
     
 
Protocol Registry Trial Results IFPMA Background Links
About this Registry

This registry serves as a global repository for information on ongoing Roche Pharmaceuticals Phase II to Phase IV clinical studies, Phase I studies in patients and Roche Diagnostics interventional studies on advanced diagnostic products.

For More Information 

Common Questions
More Frequently Asked Questions 
Overview of Clinical Trials 
Glossary of Terms 
Phase Definitions 
Field Definitions 
Roche Clinical Trial Global Policy 
Site Provided by Thomson CenterWatch

Trial information

A Study to Evaluate Renal Safety of Intravenous Bondronat (ibandronate) in Patients With Metastatic Bone Disease due to Breast Cancer

Status: No longer recruiting

Protocol number: ML19188

Sponsor: Roche SAS

Company division: Pharmaceutical

Official Scientific Title: A randomized, open label study to evaluate the renal safety of Bondronat infusions over 15 minutes or 60 minutes in patients with metastatic bone disease due to breast cancer

Brief summary: This study will evaluate renal function in patients with metastatic bone disease due to breast cancer receiving infusions of Bondronat 6mg iv over either 15 minutes or 60 minutes, every 3 weeks. Efficacy and safety of Bondronat in the 2 groups of patients will also be compared. The anticipated time on study treatment is 6 months and the target sample size is 100-500 individuals. Target sample size is 318.

Study phase: III

Study type: Interventional; Treatment; Randomized; Open Label; Active; Parallel; Safety/Efficacy study

Condition: Pain; Bone Neoplasms; Neoplasm Metastasis

Intervention type: Drug

Intervention name: ibandronate[Bondronat]

Primary outcome: 1. Creatinine clearance 28 days after last infusion

Key secondary outcomes: 1. Renal Safety: Degradation of renal function; renal tolerance up to 6 months. Efficacy: bone pain, bone events, analgesics consumption, Karnofsky index up to 6 months. Safety: AEs.

Inclusion criteria:

  • women >=18 years of age;
  • breast cancer with >= 1 bone metastasis.

Exclusion criteria:

  • bisphosphonate therapy in the 3 weeks before randomization;
  • known hypersensitivity to ibandronate or other bisphosphonates

Gender: Females

Age limits: Min: 18 Years Max: N/A (No limit)

Accepts healthy volunteers: No

Anticipated start date: January, 2006

Trial registration date: 05/04/2006

Date last updated: 9/29/2008


Link to trial result

This trial was conducted at the following locations:

France

  • Amboise
  • Angers
  • Bayonne
  • Besancon
  • Brest
  • Clermont-Ferrand
  • Gap
  • Hyeres
  • Le Chesnay
  • Nantes
  • Paris
  • Rennes
  • Rouen
  • Saint Brieuc
  • Saint Gregoire
  • Saint Jean
  • Saint-Cloud
  • Salouel
  • Strasbourg
  • Trappes
  • Valenciennes
  • Vandoeuvre-Les-Nancy
  • Villejuif

To contact Roche for more information on this trial please complete the email form below. Treatment decisions and/or suitability for a specific trial are decisions only your healthcare provider can make. If you are patient interested in any of the studies, please have your healthcare provider contact us via this website, and they will be provided with the relevant clinical trial information.

Country*
Are you a:*
Subject*
Last Name*
First Name*
Telephone
E-mail*

your email address is needed for us to reply